This study evaluates the real-world use and outcomes of dupilumab for patients with eosinophilic esophagitis (EoE).
Assessing real-world data helps confirm the effectiveness and safety of dupilumab outside controlled clinical trial settings.
Retrospective analysis of patients receiving dupilumab for EoE, focusing on symptom resolution and histological remission rates.
Dupilumab treatment significantly improves both symptoms and histological markers in EoE patients in a real-world setting.
Dupilumab is an effective therapeutic option for EoE and may be considered for patients with treatment-resistant disease.